Lisata Therapeutics Inc

NASDAQ: LSTA    
Share price (4/10/24): $3.04    
Market cap (4/10/24): $23.7 million

Credit Agreements Filter

EX-10.6
from 10-Q 8 pages Loan and Security Agreement
12/34/56
EX-10.2
from 10-Q 3 pages Second Amendment to Loan and Security Agreement
12/34/56
EX-10.1
from 10-Q 3 pages First Amendment to Loan and Security Agreement
12/34/56
EX-10.1
from 8-K 49 pages Loan and Security Agreement
12/34/56
EX-10.52
from 10-K 6 pages Mortgage Loan Note [Fixed Rate or Tied to Index]
12/34/56
EX-10.8
from 8-K 12 pages Loan Agreement by and Between the Shareholder of Beijing Ruijieao Bio-Technology Ltd. and Neostem (China), Inc. June 1, 2009
12/34/56
EX-10.4
from 8-K 12 pages Loan Agreement by and Between the Shareholder of Qingdao Niao Bio-Technology Ltd. and Neostem (China), Inc. June 1, 2009
12/34/56
EX-10.CCC
from SB-2/A 5 pages 2. the Monthly Fee Shall Be (I) a Cash Payment of $10,000; and (II) $5,000 of the Company’s Common Stock, $.001 Par Value (The “Common Stock Payment”). the Number of Shares Issued for the Common Stock Payment Shall Be Based on the Fair Market Value of the Common Stock on the First Day of the Month to Which the Payment Relates. the Shares Issued for the Common Stock Payment Shall Have Standard Piggy-Back Registration Rights. in Connection With the Foregoing, DC Makes the Following Representations: (A) DC Hereby Represents and Warrants to the Company That DC Is an “Accredited Investor” as That Term Is Defined in Rule 501(a) of Regulation D Promulgated Under the Securities Act of 1933, as Amended (The “Securities Act”). Specifically, DC Certifies That DC Is One of the Following: A Bank as Defined in Section 3(a)(2) of the Act, or a Savings and Loan Association or Other Institution as Defined in Section
12/34/56